Browse > Article
http://dx.doi.org/10.3348/kjr.2014.15.2.300

Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases  

Ryu, Yon Ju (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine)
Chun, Eun Mi (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine)
Lee, Soon Nam (Division of Hemato-Oncology, Department of Internal Medicine, Ewha Womans University School of Medicine)
Shim, Sung Shin (Department of Radiology, Ewha Womans University School of Medicine)
Publication Information
Korean Journal of Radiology / v.15, no.2, 2014 , pp. 300-304 More about this Journal
Abstract
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
Keywords
Gefitinib; Non-small cell lung cancer; Cystic change;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306   DOI   ScienceOn
2 Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in nonsmall- cell lung cancer. Drug Saf 2004;27:1081-1092   DOI   ScienceOn
3 Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006;17:372-379   DOI   ScienceOn
4 Teramoto S, Yamamoto H, Ouchi Y. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet 2003;361:1992-1993
5 Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-2424   DOI   ScienceOn
6 Topal NB, Oruc E, Gokalp G, Topal U. Atypical pulmonary metastases: radiologic appearances. Indian J Radiol Imaging 2007;17:181-185   DOI
7 Lee JC, Kim CH, Koh JS, Baek HJ, Choe DH. Lung cancer presenting as an asymptomatic pneumatocele. Intern Med 2008;47:1757-1758   DOI
8 Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500   DOI   ScienceOn
9 Barnardt P, du Toit J. The radiological appearance of metastatic cystic lesions. SA Journal of Radiology 2011:131-133
10 Zee YK, Chin TM, Wong AS. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009;27:e145-e146   DOI
11 Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005;28:103-113   DOI
12 Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-424   DOI